Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

As an oncologist with more than 25 years of experience across clinical care, research, drug and device development, and ...

Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

The BioInnovation Institute (BII) has expanded a network striving to develop treatments for cardiometabolic diseases and ...

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

Across events and general day-to-day industry updates, one term has dominated market access conversations in 2026: Most Favoured Nation. Now, debates over pricing in the US are nothing new – far from ...

Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell ...

Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in the third ...

The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...

While praising the breadth of its pipeline, AstraZeneca has launched a three-year cost-cutting programme that will aim to ...

The Novartis Pavillon in Park South of the Novartis Campus in Basel, Switzerland. Novartis's third-quarter results included a ...